1-s2.0-S0166093422000222-main (1).pdf (1.86 MB)
Download file

Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility.

Download (1.86 MB)
journal contribution
posted on 03.02.2022, 11:42 authored by Carolina Rosadas, Maryam Khan, Eleanor Parker, Federica Marchesin, Ksenia Katsanovskaja, Macià Sureda-Vives, Natalia Fernandez, Paul Randell, Ruth Harvey, Alice Lilley, Benjamin HL Harris, Mohamed Zuhair, Michael Fertleman, Samreen Ijaz, Steve Dicks, Charlotte-Eve Short, Rachael Quinlan, Graham P Taylor, Kai Hu, Paul McKay, Annachiara Rosa, Chloe Roustan, Mark Zuckerman, Kate El Bouzidi, Graham Cooke, Barnaby Flower, Maya Moshe, Paul Elliott, Alexandra J Spencer, Teresa Lambe, Sarah C Gilbert, Hugh Kingston, J Kenneth Baillie, Peter JM Openshaw, Malcolm G Semple, Peter Cherepanov, Myra O McClure, Richard S Tedder, ISARIC4C Investigators
Accurate and sensitive detection of antibody to SARS-CoV-2 remains an essential component of the pandemic response. Measuring antibody that predicts neutralising activity and the vaccine response is an absolute requirement for laboratory-based confirmatory and reference activity. The viral receptor binding domain (RBD) constitutes the prime target antigen for neutralising antibody. A double antigen binding assay (DABA), providing the most sensitive format has been exploited in a novel hybrid manner employing a solid-phase S1 preferentially presenting RBD, coupled with a labelled RBD conjugate, used in a two-step sequential assay for detection and measurement of antibody to RBD (anti-RBD). This class and species neutral assay showed a specificity of 100% on 825 pre COVID-19 samples and a potential sensitivity of 99.6% on 276 recovery samples, predicting quantitatively the presence of neutralising antibody determined by pseudo-type neutralisation and by plaque reduction. Anti-RBD is also measurable in ferrets immunised with ChadOx1 nCoV-19 vaccine and in humans immunised with both AstraZeneca and Pfizer vaccines. This assay detects anti-RBD at presentation with illness, demonstrates its elevation with disease severity, its sequel to asymptomatic infection and its persistence after the loss of antibody to the nucleoprotein (anti-NP). It also provides serological confirmation of prior infection and offers a secure measure for seroprevalence and studies of vaccine immunisation in human and animal populations. The hybrid DABA also displays the attributes necessary for the detection and quantification of anti-RBD to be used in clinical practice. An absence of detectable anti-RBD by this assay predicates the need for passive immune prophylaxis in at-risk patients.

Funding

Crick (Grant ID: 10015, Grant title: STP Structural Biology) Crick (Grant ID: 10061, Grant title: Cherepanov FC001061) Crick (Grant ID: 10030, Grant title: McCauley FC001030)

History